Woodside Energy Group (NYSE:WDS) H2 2025 Earnings call February 23, 2026 06:00 PM ET Company ParticipantsBaden Moore - Head of Resources and Energy ReseaarchDale Koenders - Head of Energy and Utilities ResearchGordon Ramsay - Head of Global Energy ResearchGraham Tiver - CFOHenry Meyer - Executive DirectorMeg O'Neill - CEO and Managing DirectorNik Burns - Head of Energy ResearchTom Allen - Executive DirectorConference Call ParticipantsRob Koh - Equity Research AnalystSarah Kerr - Energy Research AnalystSaul ...

Financial Data and Key Metrics Changes - In 2025, the company achieved a record annual production of 198.8 million barrels of oil equivalent, exceeding full-year guidance [3] - Underlying net profit after tax was reported at $2.6 billion, with record production offsetting lower realized prices compared to 2024 [3] - Free cash flow generated was $1.9 billion, with a total fully franked full-year dividend of $1.12 per share, representing a payout ratio of 80% of underlying NPAT [4][25] Business Line Data and Key Metrics Changes - The Sangomar project maintained nameplate production of 100,000 barrels per day with nearly 99% reliability, contributing $2.6 billion to EBITDA since startup [8] - The Beaumont New Ammonia project commenced production in December 2025, with expectations for lower carbon ammonia production targeted for the second half of 2026 [9] - The Scarborough Energy Project was reported at 94% completion at year-end, on track for first LNG cargo in Q4 2026 [10] Market Data and Key Metrics Changes - Oil demand is forecasted to remain resilient due to the difficulty of decarbonizing hard-to-abate sectors, with strong customer demand for Sangomar oil noted [16] - Approximately 75% of LNG volumes for 2026-2028 are contracted, with a mix of oil-linked and gas hub link exposure [17] - The company has contracted 4.7 million tons of new LNG supply to Tier One end customers, reinforcing its position as a reliable energy supplier [17] Company Strategy and Development Direction - The company is focused on disciplined execution to deliver long-term value, maximizing performance from its base business and creating future opportunities for growth [5] - Strategic partnerships, such as those with Stonepeak and Williams for the Louisiana LNG project, are aimed at reducing capital commitments and de-risking investments [22] - Sustainability performance is emphasized as a key component of business success, with a target of reducing greenhouse gas emissions by 15% achieved [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in ongoing demand for LNG as a reliable energy source amid global energy security concerns [16] - The company anticipates a transition year in 2026 with significant activities planned, including a major turnaround at Pluto and the ramp-up of Scarborough [38] - The management remains committed to maintaining a strong balance sheet and liquidity position while delivering solid shareholder returns [25] Other Important Information - The company achieved a 4% reduction in unit production costs through disciplined cost management [8] - Significant safety milestones were reported, with no high-consequence injuries recorded during the year [6] - The company plans to continue optimizing its marketing portfolio and layering in Louisiana LNG offtake [27] Q&A Session Summary Question: Update on Louisiana LNG sell-down progress - Management is pleased with the sell-down process and targets an additional 20% sell-down, reducing Woodside's capital commitment to $9.9 billion [32] Question: Dividend outlook for 2026 - Management indicated flexibility in the capital management framework to consider special dividends or buybacks, depending on performance and market conditions [38] Question: Decommissioning activities and Bass Strait platform removal - Decommissioning activities are ongoing, with major campaigns planned for 2026 and platform removals targeted for 2027 [42] Question: Unit production costs and Beaumont's impact - Management clarified that costs associated with Beaumont will be separate from traditional production costs, with transparency in future reporting [44][46] Question: Contracting status for Beaumont New Ammonia - The company is seeing genuine interest in ammonia products and is layering contracts as the facility ramps up production [60] Question: Production guidance and decline rates - Management noted that natural field decline and maintenance activities are factored into production guidance, with ongoing assessments of Sangomar's performance [86]

Woodside Energy Group (NYSE:WDS) H2 2025 Earnings call February 23, 2026 06:00 PM ET Speaker5Good morning, welcome to Woodside's 2025 full year results presentation. We are presenting from Sydney, and I would like to begin by acknowledging the traditional custodians of this land, the Gadigal people of the Eora Nation, and pay my respects to their elders, past and present. Today, I'm joined on the call by our Chief Financial Officer, Graham Tiver. Together, we will provide an overview of our full year 2025 p ...

Vir Biotechnology (NasdaqGS:VIR) Q4 2025 Earnings call February 23, 2026 05:30 PM ET Company ParticipantsJason O'Byrne - EVP and Interim CFOJohann de Bono - Regius Professor of Cancer ResearchJosh Schimmer - Senior Managing DirectorKiki Patel - Head of Investor RelationsMarianne De Backer - CEO and DirectorMark Eisner - EVP and Chief Medical OfficerPatrick Trucchio - Managing Director of Equity ResearchSean McCutcheon - VP of Biotechnology Equity ResearchConference Call ParticipantsAlec Stranahan - VP and S ...

Vir Biotechnology (NasdaqGS:VIR) Q4 2025 Earnings call February 23, 2026 05:30 PM ET Company ParticipantsJason O'Byrne - EVP and Interim CFOJohann de Bono - Regius Professor of Cancer ResearchJosh Schimmer - Senior Managing DirectorKiki Patel - Head of Investor RelationsMarianne De Backer - CEO and DirectorMark Eisner - EVP and Chief Medical OfficerPatrick Trucchio - Managing Director of Equity ResearchSean McCutcheon - VP of Biotechnology Equity ResearchConference Call ParticipantsAlec Stranahan - VP and S ...

Financial Data and Key Metrics Changes - R&D expenses for 2025 were $456 million, a decrease of $51 million or 10% from $507 million in 2024 [42] - SG&A expenses decreased to $92 million in 2025 from $119 million in the prior year, representing a 23% reduction [42] - The net loss for 2025 was $438 million, compared to $522 million in 2024 [43] - The company started 2026 with approximately $782 million in cash, cash equivalents, and investments, not including the upfront cash and equity from the Astellas collaboration [43] Business Line Data and Key Metrics Changes - The collaboration with Astellas is focused on the development and commercialization of VIR-5500, a T-cell engager for prostate cancer [6][12] - The total potential in combined upfront and milestone payments from the collaboration is $1.7 billion, with a 50/50 profit-sharing arrangement in the U.S. [13][41] Market Data and Key Metrics Changes - Prostate cancer represents a significant global health burden, with 1 in 8 men diagnosed in their lifetime and a five-year survival rate of only 30% for patients with metastatic castration-resistant prostate cancer (mCRPC) [9] - There are approximately 100,000 mCRPC patients in the U.S. and Europe, indicating a substantial unmet need for novel treatment solutions [9] Company Strategy and Development Direction - The strategic collaboration with Astellas aims to accelerate the development of VIR-5500 across various lines of prostate cancer, unlocking significant market opportunities [7][12] - The company plans to initiate dose expansion cohorts in late-line mCRPC monotherapy and combinations in the second quarter of 2026 [38][61] - The PRO-XTEN platform is expected to enable the development of next-generation T-cell engagers for solid tumors, with plans for further preclinical programs [44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of VIR-5500, highlighting its favorable safety and efficacy profile based on emerging Phase I data [6][18] - The collaboration with Astellas is seen as a key factor in maximizing the potential of VIR-5500 and expanding the company's pipeline [44][45] Other Important Information - The Phase I clinical study of VIR-5500 showed a favorable safety profile with no observed dose-limiting toxicities and limited cytokine release syndrome [30][32] - The company is positioned to transition into expansion cohorts and plans to continue dose optimization to meet FDA requirements [38][39] Q&A Session Summary Question: Can you comment on the range of PSA responses seen by prior line of therapies, particularly with regard to prior radiotherapy? - Management noted strong PSA responses, particularly at higher doses, but specific effects of prior treatments on PSA responses were difficult to determine due to the heavily pretreated population [52][54] Question: What are the next steps before moving to Phase 3 with Astellas? - The company plans to initiate expansion cohorts in Q2 2026, focusing on late-line mCRPC as a monotherapy and combinations with other therapies [60][61] Question: How does the larger cohort of patients evaluated on VIR-5500 evolve the thinking about its positioning within the treatment paradigm? - Management indicated plans to address a broad range of patients, including late-line mCRPC and combinations, highlighting the high unmet need in these populations [66] Question: Can you provide more information on the go-forward dose? - The go-forward dose is expected to be in the range of 3,000 to 3,500 micrograms per kilogram, with compelling dose-response data observed [76][77]

Paymentus (NYSE:PAY) Q4 2025 Earnings call February 23, 2026 05:00 PM ET Company ParticipantsCraig Maurer - Managing Director of ResearchDavid Hanover - Head of Investor RelationsDushyant Sharma - CEOSanjay Kalra - CFOWill Nance - VPConference Call ParticipantsDarrin Peller - Managing Director and Senior AnalystMadison Suhr - Research AnalystTien-Tsin Huang - Senior AnalystOperatorGood day, and welcome to the fourth quarter and full year 2025 Paymentus Earnings Conference Call. This call is being recorded. ...

Allison Transmission (NYSE:ALSN) Q4 2025 Earnings call February 23, 2026 05:00 PM ET Company ParticipantsAngel Castillo - Executive DirectorCraig Price - President and Business Unit Leader of Off-Highway Drive & Motion SystemsDave Graziosi - Chair, President, and CEOFred Bohley - COO and Transmission Business Unit LeaderJackie Bolles - Executive Director of Treasury and Investor RelationsJerry Revich - Managing DirectorScott Mell - CFO and TreasurerTami Zakaria - Executive DirectorConference Call Participan ...

Cannae (NYSE:CNNE) Q4 2025 Earnings call February 23, 2026 05:00 PM ET Company ParticipantsBryan Coy - CFOIan Zaffino - Managing DirectorJamie Lillis - Managing Director of Investor RelationsRyan Caswell - CEOConference Call ParticipantsKenneth Lee - VP and Senior Equity Research AnalystOperatorGood afternoon, ladies and gentlemen, and welcome to the Cannae Holdings, Inc. 4th Quarter and Full Year 2025 Financial Results Conference Call. During today's presentation, all parties will be in a listen-only mode. ...

Clearway Energy (NYSE:CWEN) Q4 2025 Earnings call February 23, 2026 05:00 PM ET Company ParticipantsAkil Marsh - Senior Director of Investor RelationsCraig Cornelius - President and CEOHannah Velásquez - VP and Equity ResearchHeidi Hauch - VPSarah Rubenstein - CFOConference Call ParticipantsAngie Storozynski - Senior Equity Research Analyst and US Utilites & PowerJustin Clare - Managing Director and Senior Research AnalystMark Jarvi - Equity Research AnalystNelson Ng - VP and Equity AnalystOperatorThank you ...